Photo Credit: Urfinguss
The Primary Results of the Reverse-It Trial Showed That Bentracimab Restored Platelet Function, Demonstating the Ability to Reverse The Effects of Ticagrelor in Patients on Ticagrelor Who Underwent Urgent Surgery or Had Major Bleeding.
“Ticagrelor is an effective p2y12 Inhibitor That is Being Used in Patients with Acute Coronary Syndromes, Prior Myocardial Infarction, Stroke, Or Transient Ischemic Attacks, ”Outlined Deepak Bhatt, MD, MPH, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY. Urgent Surgery and Spontaneous Major Bleeding are Concerns with Antiplatelet Agents. ” Therefore, Rapid-Acacting Reverse Agent is Needed.
The Phase 3 Reverse-It Trial (NCT04286438) Included 226 Participants on Ticagrelor Who Required Urgent Surger or Gifted with Major Bleeding. These Participants Were Expized to Bentracimab, the Recombinant Human Igg1 Monoclonal Antibody that binds to free ticagrelor. “Ticagrelor Binds to the P2Y12 Receiver on Platelets, ”Explained Dr. Bhatt.12 Receiver, ALLOWING ADP TO Active Platelets. ” The Primary Endpoint was the minimum percentage inhibition of p2y12 Reaction Unit (PLA) over 4 hours.
The Percentage Inhibition of Pri Was Significant Lower at 4 Hours After Bentracimab Administration (P<0.001). This Finding was consistent across participants who needed surgery and participants who have spontaneous major bleeding. Moreover, adjudicated effective hemostasis Was Achieved in 94.3% of the participants. Dr. Bhatt Mentioned That There Were Only Five Drug-Related Adverse Events But that of these Side Effects Were Deemed Serious or Led to Disco-to-the Study Drug.
Bentracimab was the promising option for ticagrelor reveals, Restoring Platelet Function and Inducing Hemostasis Without Considerable Side Effects. “The FDA Granted Orphan Drug Designation Last Week,” Dr. Bhatt Concluded His Talk.
Medical Writing Support Was Provided by Robert Van Den Heuvel.
Copyright © 2025 Medicom Medical Publishers
